Home › NDC Lookup › RxCUI directory › RxCUI 728225

Maraviroc 300 MG Oral Tablet — RxCUI 728225

RxNorm drug concept · Semantic clinical drug
RxCUI 728225 Semantic clinical drug · SCD ● Current RxNorm concept 18 FDA products 18 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI728225
Official nameMaraviroc 300 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped18
Package NDCs mapped18
Reported Medicaid activity (SDUD)1,074 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Maraviroc: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Maraviroc is not a cure for HIV. It's an antiviral medication that helps control CCR5-tropic HIV-1 by blocking the virus from entering your immune cells. When taken consistently as...
  • What exactly is maraviroc treating — is it a cure for HIV?
  • Maraviroc only works against one specific type of HIV called CCR5-tropic HIV-1. Some people have a strain that uses a different receptor (CXCR4-tropic) or one that uses both — and...
  • Why do I need a test before I can even start this medication?
📖 Read our full Maraviroc guide →

🕸️ Concept Web — How Maraviroc 300 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Maraviroc 300 MG Oral Tablet RxCUI 728225

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Maraviroc 620216
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Selzentry 728648
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Maraviroc Oral Tablet 728222
    • Maraviroc Oral Product 1165075
    • Maraviroc Pill 1165076
    • Maraviroc Oral Tablet [Selzentry] 729200
    • Selzentry Oral Product 1178366
    • Selzentry Pill 1178367
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Maraviroc 300 MG SCDC · 728224
  • Maraviroc Oral Tablet SCDF · 728222
  • Maraviroc Oral Product SCDG · 1165075
  • Maraviroc Pill SCDG · 1165076

Brand-Name Concepts

  • Maraviroc 300 MG Oral Tablet [Selzentry] SBD · 729203
  • Maraviroc 300 MG [Selzentry] SBDC · 729202
  • Maraviroc Oral Tablet [Selzentry] SBDF · 729200
  • Selzentry Oral Product SBDG · 1178366
  • Selzentry Pill SBDG · 1178367
  • Selzentry BN · 728648

📦 FDA Products & Package NDCs

18 products · 18 package NDCs
18 package NDCs map to RxCUI 728225 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
31722-0579-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-579-60) Maraviroc Camber Pharmaceuticals, Inc. 2022-02-06
31722-0580-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-580-60) Maraviroc Camber Pharmaceuticals, Inc. 2022-02-06
49702-0223-18 60 TABLET, FILM COATED in 1 BOTTLE (49702-223-18) SELZENTRY ViiV Healthcare Company 2011-05-16
49702-0224-18 60 TABLET, FILM COATED in 1 BOTTLE (49702-224-18) SELZENTRY ViiV Healthcare Company 2011-05-16
49702-0260-55 1 KIT in 1 CARTON (49702-260-55) * 230 mL in 1 BOTTLE SELZENTRY ViiV Healthcare Company 2020-10-30
50090-8005-00 60 TABLET, FILM COATED in 1 BOTTLE (50090-8005-0) Maraviroc A-S Medication Solutions 2026-06-25
68475-0007-01 60 TABLET, FILM COATED in 1 BOTTLE (68475-007-01) Maraviroc Navinta LLC 2025-06-23
68475-0008-01 60 TABLET, FILM COATED in 1 BOTTLE (68475-008-01) Maraviroc Navinta LLC 2025-06-23
68554-3079-00 60 TABLET, FILM COATED in 1 BOTTLE (68554-3079-0) Maraviroc Hetero Labs Limited 2022-02-06
68554-3080-00 60 TABLET, FILM COATED in 1 BOTTLE (68554-3080-0) Maraviroc Hetero Labs Limited 2022-02-06
70710-1930-06 60 TABLET, FILM COATED in 1 BOTTLE (70710-1930-6) Maraviroc Zydus Pharmaceuticals USA Inc. 2025-05-23
70710-1931-06 60 TABLET, FILM COATED in 1 BOTTLE (70710-1931-6) Maraviroc Zydus Pharmaceuticals USA Inc. 2025-05-23
72319-0024-02 60 TABLET, FILM COATED in 1 BOTTLE (72319-024-02) Maraviroc i3 Pharmaceuticals, LLC 2023-09-15
72319-0025-02 60 TABLET, FILM COATED in 1 BOTTLE (72319-025-02) Maraviroc i3 Pharmaceuticals, LLC 2023-09-15
72865-0231-60 60 TABLET, FILM COATED in 1 BOTTLE (72865-231-60) Maraviroc XLCare Pharmaceuticals Inc. 2023-06-01
72865-0232-60 60 TABLET, FILM COATED in 1 BOTTLE (72865-232-60) Maraviroc XLCare Pharmaceuticals Inc. 2023-06-01
73141-0024-02 60 TABLET, FILM COATED in 1 BOTTLE (73141-024-02) Maraviroc A2A Integrated Pharmaceuticals 2024-05-16
73141-0025-02 60 TABLET, FILM COATED in 1 BOTTLE (73141-025-02) Maraviroc A2A Integrated Pharmaceuticals 2024-05-16
Observed labelers: ViiV Healthcare Company (3) · A2A Integrated Pharmaceuticals (2) · Camber Pharmaceuticals, Inc. (2) · Hetero Labs Limited (2) · i3 Pharmaceuticals, LLC (2) · Navinta LLC (2) · +3 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.